News stories about Amicus Therapeutics (NASDAQ:FOLD) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Amicus Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.2120244746437 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
FOLD has been the topic of a number of research analyst reports. Leerink Swann reiterated an “outperform” rating and set a $17.00 price objective (down previously from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. Goldman Sachs Group reiterated a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 6th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, Bank of America raised their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $18.31.
Shares of Amicus Therapeutics (FOLD) opened at $15.72 on Friday. The firm has a market cap of $2,638.69, a P/E ratio of -8.59 and a beta of 1.72. Amicus Therapeutics has a 1-year low of $5.07 and a 1-year high of $16.60. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The company’s quarterly revenue was up 419.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) earnings per share. equities research analysts predict that Amicus Therapeutics will post -1.56 EPS for the current fiscal year.
In related news, CEO John F. Crowley sold 449,295 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the completion of the sale, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,455,760.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Daphne Quimi sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $117,760.00. Following the completion of the transaction, the senior vice president now directly owns 62,676 shares of the company’s stock, valued at approximately $922,590.72. The disclosure for this sale can be found here. Insiders have sold 718,920 shares of company stock valued at $10,263,669 over the last 90 days. 3.40% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics (NASDAQ:FOLD) Getting Somewhat Favorable Media Coverage, Analysis Shows” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/amicus-therapeutics-fold-earns-daily-news-sentiment-score-of-0-06.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.